Griffiths CEM - Search Results

1

Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.

Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Among authors: griffiths cem. Nat Commun. 2021 Aug 6;12(1):4741. doi: 10.1038/s41467-021-25066-9. Nat Commun. 2021. PMID: 34362923 Free PMC article.

2

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD; British Association of Dermatologists. Smith CH, et al. Br J Dermatol. 2005 Sep;153(3):486-97. doi: 10.1111/j.1365-2133.2005.06893.x. Br J Dermatol. 2005. PMID: 16120132 No abstract available.

3

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

Warren RB, Griffiths CE. Warren RB, et al. Br J Dermatol. 2005 Nov;153(5):869-73. doi: 10.1111/j.1365-2133.2005.06880.x. Br J Dermatol. 2005. PMID: 16225593 Review.

4

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Reich K, et al. Lancet. 2005 Oct 15-21;366(9494):1367-74. doi: 10.1016/S0140-6736(05)67566-6. Lancet. 2005. PMID: 16226614 Clinical Trial.

5

Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.

Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CE, Crook MA, Barker JN, Smith CH. Campalani E, et al. Br J Dermatol. 2006 Feb;154(2):345-52. doi: 10.1111/j.1365-2133.2005.06950.x. Br J Dermatol. 2006. PMID: 16433808

6

Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines.

Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, Doria A. Griffiths CE, et al. Clin Exp Rheumatol. 2006 Jan-Feb;24(1 Suppl 40):S72-8. Clin Exp Rheumatol. 2006. PMID: 16466629 Review.

7

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Br J Dermatol. 2006 Jun;154(6):1161-8. doi: 10.1111/j.1365-2133.2006.07237.x. Br J Dermatol. 2006. PMID: 16704649 Clinical Trial.

8

Infliximab for the treatment of psoriasis.

Kleyn CE, Griffiths CE. Kleyn CE, et al. Expert Opin Biol Ther. 2006 Aug;6(8):797-805. doi: 10.1517/14712598.6.8.797. Expert Opin Biol Ther. 2006. PMID: 16856801 Review.

9

Pathogenesis and clinical features of psoriasis.

Griffiths CE, Barker JN. Griffiths CE, et al. Lancet. 2007 Jul 21;370(9583):263-271. doi: 10.1016/S0140-6736(07)61128-3. Lancet. 2007. PMID: 17658397 Review.

10

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Reich K, et al. Eur J Dermatol. 2007 Sep-Oct;17(5):381-6. doi: 10.1684/ejd.2007.0234. Epub 2007 Aug 2. Eur J Dermatol. 2007. PMID: 17673380 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

574 results

Search Page